Kardigan, Inc. Investment Income, Interest
Kardigan, Inc. (KARD) reported Investment Income, Interest of $2.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Kardigan, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.77M, a 158.90% increase year-over-year.
- Kardigan, Inc. investment income, interest for the quarter ending 2025-06-30 was $1.07M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month |
|---|---|---|
| 2026-06-30 | $2.77M 10-Q · filed 2026-08-11 | $5.56M 10-Q · filed 2026-08-11 |
| 2025-06-30 | $1.07M 10-Q · filed 2026-08-11 | $1.90M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |